Evidence map›Paper›PMID 40918096›Full record

ArticleFrontiers in immunology2025

A genome-wide association study identifies new loci associated with response to SARS-CoV-2 mRNA-1273 vaccine in a cohort of healthy healthcare workers.

Antonio José Cabrera-Serrano, Lucía Ruiz-Durán, Juan Francisco Gutiérrez-Bautista, María Carretero-Fernández, Rob Ter Horst, Yang Li, Fernando Jesús Reyes-Zurita, Francisco José García-Verdejo, Mihai G Netea, Pedro Sánchez-Rovira and 3 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Antonio José Cabrera-SerranoGenomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Parque Tecnológico de Ciencias de la Salud (PTS), Granada, Spain.
Lucía Ruiz-DuránGenomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Parque Tecnológico de Ciencias de la Salud (PTS), Granada, Spain.
Juan Francisco Gutiérrez-Bautista *Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Parque Tecnológico de Ciencias de la Salud (PTS), Granada, Spain.
María Carretero-FernándezGenomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Parque Tecnológico de Ciencias de la Salud (PTS), Granada, Spain.
Rob Ter HorstDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands.
Yang LiDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands.
Fernando Jesús Reyes-ZuritaDepartment of Biochemistry and Molecular Biology I, Faculty of Sciences, University of Granada, Granada, Spain.
Francisco José García-VerdejoGenomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Parque Tecnológico de Ciencias de la Salud (PTS), Granada, Spain.
Mihai G NeteaDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands.
Pedro Sánchez-RoviraGenomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Parque Tecnológico de Ciencias de la Salud (PTS), Granada, Spain.
Miguel Ángel López-NevotInstituto de Investigación Biosanitaria IBs.Granada, Granada, Spain.
Antonio SampedroInstituto de Investigación Biosanitaria IBs.Granada, Granada, Spain.
Juan Sainz *Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Parque Tecnológico de Ciencias de la Salud (PTS), Granada, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The COVID-19 pandemic had significant global public health consequences, affecting over 200 countries and regions by 2020. The development and efficacy of specific vaccines, such as the mRNA-1273 (Spikevax Materials and methods: We conducted three genome-wide association studies (GWAS) in a cohort of Spanish healthcare workers, analyzing anti-S IgG levels at one-month post-vaccination (n=567), at three months post-vaccination (n=447), and the difference in circulating anti-S IgG levels between these two time points (n=447). Results: We identified fourteen novel loci associated with increasing concentrations of anti-S IgG post-vaccination ( Discussion: In conclusion, this study highlights the complex interplay of genetic factors influencing the immune response to vaccination, particularly through modulation of B cell activity, immune signaling pathways, and metabolic processes. The identification of genetic variants could inform future strategies to enhance vaccine efficacy and provide a deeper understanding of individual variability in vaccine responses, especially for COVID-19 and other viral infections.

Indexed as

COVID-19COVID-19 VaccinesSARS-CoV-22019-nCoV Vaccine mRNA-1273AdultAntibodies, ViralCohort StudiesFemaleGenetic LociGenome-Wide Association StudyHealth PersonnelHumansImmunoglobulin GMaleMiddle AgedPolymorphism, Single Nucleotide2019-nCoV Vaccine mRNA-1273Antibodies, ViralCOVID-19 VaccinesImmunoglobulin GSpike Glycoprotein, Coronaviruscirculating IgG levelsgenetic variantsGWASIgG decaySARS-CoV-2

Identifiers

PMID40918096
PMCPMC12409172

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.